Evidence map›Paper›PMID 34393439›Full record

ArticleBioinformation2021

Molecular docking of potential inhibitors with the mTOR protein.

Jh Shazia Fathima, Jayaraman Selvaraj, Venkatacalam Sivabalan, Umapathy Vidhya Rekha, Rajagopal Ponnulakshmi, Veeraraghavan Vishnupriya, Malathi Kullappan, Radhika Nalinakumari Sreekandan, Surapaneni Krishna Mohan, Periyasamy Vijayalakshmi

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioinformation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Combinatorial chemistry & high throughput screening · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Jh Shazia FathimaDepartment of Oral and Maxillofacial Pathology, Ragas Dental College and Hospitals, Chennai, India.
Jayaraman SelvarajDepartment of Biochemistry,Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai - 600 077, India.
Venkatacalam SivabalanDepartment of Biochemistry, KSR Institute of Dental Sciences and Research, Thiruchengodu-637215, Indi.
Umapathy Vidhya RekhaDepartment of Public Health Dentistry, Sree Balaji Dental College and Hospital, Pallikaranai, Chennai-600 100, India.
Rajagopal PonnulakshmiCentral Research Laboratory, Meenakshi Academy of Higher Education and Research (Deemed to be University), Chennai-600 078, India.
Veeraraghavan VishnupriyaDepartment of Biochemistry,Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai - 600 077, India.
Malathi KullappanDepartment of Research, Panimalar Medical College Hospital & Research Institute, Varadharajapuram, Poonamallee, Chennai - 600 123, India.
Radhika Nalinakumari SreekandanDepartment of Clinical Skills & Simulation, Panimalar Medical College Hospital & Research Institute, Varadharajapuram, Poonamallee, Chennai - 600 123, India.
Surapaneni Krishna MohanDepartment of Biochemistry and Department of Clinical Skills & Simulation, Department of Research, Panimalar Medical College Hospital & Research Institute, Varadharajapuram, Poonamallee, Chennai - 600 123.
Periyasamy VijayalakshmiDBT-BIF Centre, PG & Research Department of Biotechnology & Bioinformatics, Holy Cross College (Autonomous), Trichy, Tamilnadu, India.
Almas Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The mTOR (mammalian or mechanistic Target of Rapamycin) is linked with oral cancer. Therefore, it is of interest to study the molecular docking-based binding of paclitaxel (a FDA approved drug for oral cancer) and its analogues with mTOR. Hence, we report the binding features of 10-Deacetyltaxol, 7-Epi-10-deacetyltaxol, 7-Epi-Taxol and 6alpha-Hydroxypaclitaxel with mTOR for further consideration.

Indexed as

analoguesmolecular dockingmTORoral cancerpaclitaxel

Identifiers

PMID34393439
PMCPMC8340694
OpenAlexW3129206293

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.